Recent clinical trials have showed that allogeneic Vδ2 γδT cells expanded from healthy donors exhibited high cytotoxicity against hematologic cancers and had low risk of graft-versus-host disease (GVHD) due to the unique MHC-independent recognition mechanism of γδT cells (114). The gene discussed is HLA-C; the disease is graft versus host disease.